Premium
Phosphatidylethanolamine‐Binding Proteins, Including RKIP, Exhibit Affinity for Phosphodiesterase‐5 Inhibitors
Author(s) -
Dadvar Poupak,
Kovanich Duangnapa,
Folkers Gert E.,
Rumpel Klaus,
Raijmakers Reinout,
Heck Albert J. R.
Publication year - 2009
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.200900452
Subject(s) - interactome , biochemistry , chemistry , in silico , plasma protein binding , phosphatidylethanolamine , proteomics , protein–protein interaction , microbiology and biotechnology , binding protein , biology , phospholipid , phosphatidylcholine , membrane , gene
Identifying protein “interactors” of drugs is of great importance to understand their mode of action and possible cross‐reactivity to off‐target protein binders. In this study, we profile proteins that bind to PF‐3717842, a high‐affinity phosphodiesterase‐5 (PDE5) inhibitor, by using a refined affinity pulldown approach with PF‐3717842 immobilized beads. By performing these pulldowns in rat testis tissue lysate, we strongly and specifically enriched for PDE5 and a few other PDEs. In addition to these expected affinity‐enriched proteins we also detect rodent‐specific phosphatidylethanolamine‐binding protein 2 (PEBP2), as a putative binder to the PDE5 inhibitor. By using recombinant forms of the related murine mPEBP2, mPEBP1 and human hPEBP1 (also known as Raf kinase inhibitor protein or RKIP) we confirm that they all can bind strongly to immobilized as well as soluble PF‐3717842. As the phosphatidylethanolamine‐binding proteins are involved in various important signal transduction pathways, the synthetic PDE5 inhibitor used here might form a platform to synthesize enhanced binders/inhibitors of the family of PEBP proteins. Our approach shows how chemical proteomics might be used to profile the biochemical space (interactome) of small molecule inhibitors.